Robert Lowsky

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Robert Lowsky sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Robert Lowsky: 6 sponsored US clinical trials, none currently recruiting.

Robert Lowsky sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 2 trials.

Upper-quartile sponsor footprint

Robert Lowsky sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

6 total, page 1 of 1

COMPLETED Phase 2

CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML

NCT04151706
COMPLETED Phase 1

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

NCT02927964
COMPLETED Phase 2

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

NCT02424968
COMPLETED Phase 1

A Phase I/II Study of Intratumoral Injection of SD-101

NCT02254772
TERMINATED Phase 1

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT01745354
COMPLETED Phase 1

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

NCT01523223

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2

Therapeutic Areas

Acute Myeloid Leukemia 2
T Cell Non-Hodgkin Lymphoma 1
Chronic Myeloid Leukemia 1
Hodgkin Lymphoma 1
Myeloproliferative Neoplasm 1
Acute Leukemia 1
Myelodysplastic Syndrome 1
B-Cell Non-Hodgkin Lymphoma 1
Acute Lymphoblastic Leukemia 1
Chronic Lymphocytic Leukemia 1

How the Robert Lowsky early-phase archive is shaped

6 indexed studies, none listed as recruiting (0% open); 5 completed (83%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Acute Myeloid Leukemia (2 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Robert Lowsky: archived-pipeline peers nationwide

Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Robert Lowsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Robert Lowsky23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan Branch10xBio22nd Century Group3-C Institute for Social Development3 Waves Wellness
Robert Lowsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Robert Lowsky sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Robert Lowsky page

6 registered trials is a research-attention snapshot, not an endorsement of Robert Lowsky or any single study.

  • None of Robert Lowsky's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acute Myeloid Leukemia is the condition Robert Lowsky studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Robert Lowsky pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.